Abstract
Cancer is a disease of aging, and so with the increasing age of the US population, the incidence of cancer is also increasing. Furthermore the global burden of cancer continues to increase largely because of aging and growth of the world population together with increasing smoking rates in economically developing countries. Tumor formation is critically dependent upon two processes—initiation and progression. The initiation step is mediated by DNA damage, which causes activating mutations in proto-oncogenes and inactivation of tumor suppressor genes in many cancers. This is then thought to facilitate tumor progression and metastasis. Cyclooxygenase-2 (COX-2) is upregulated at an early stage in tumorigenesis and has been implicated as an important mediator of proliferation through the increased formation of bioactive arachidonic acid (AA) metabolites such as prostaglandin E2. Significantly, we have found that COX-2-mediated AA metabolism also results in the formation of heptanone-etheno (Hε)-DNA adducts. Furthermore, we showed that the Hε-DNA adducts arose from the reaction of DNA with the lipid hydroperoxide-derived bifunctional electrophile, 4-oxo-2(E)-nonenal (ONE). Similarly, 5-lipoxoygenase-mediated AA metabolism also results in the formation of ONE-derived DNA adducts. The resulting Hε-DNA adducts are highly mutagenic in mammalian cell lines suggesting that these pathways could be (in part) responsible for the somatic mutations observed in tumorigenesis. As approximately 80% of cancers arise from somatic mutations, this provides an additional link between the upregulation of COX-2 and tumorigenesis.
Similar content being viewed by others
References
Mangal, D., Vudathala, D. K., Park, J. H., Lee, S. H., Penning, T. M., & Blair, I. A. (2009). Analysis of 7,8-dihydro-8-oxo-2′-deoxyguanosine in cellular DNA during oxidative stress. Chemical Research in Toxicology, 22, 788–797.
Park, J. H., Mangal, D., Tacka, K. A., Quinn, A. M., Harvey, R. G., Blair, I. A., et al. (2008). Evidence for the aldo-keto reductase pathway of polycyclic aromatic trans-dihydrodiol activation in human lung A549 cells. Proceedings of the National Academy of Sciences USA, 105, 6846–6851.
Gonzalez, F. J. (2005). Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutation Research, 569, 101–110.
Ames, B. N., Shigenaga, M. K., & Hagen, T. M. (1993). Oxidants, antioxidants, and the degenerative diseases of aging. Proceedings of the National Academy of Sciences USA, 90, 7915–7922.
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., et al. (2011). Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature, 475, 106–109.
Churg, A. (2003). Interactions of exogenous or evoked agents and particles: the role of reactive oxygen species. Free Radical Biology & Medicine, 34, 1230–1235.
Cadet, J., Delatour, T., Douki, T., Gasparutto, D., Pouget, J. P., Ravanat, J. L., et al. (1999). Hydroxyl radicals and DNA base damage. Mutation Research, 424, 9–21.
Zhu, P., Oe, T., & Blair, I. A. (2008). Determination of cellular redox status by stable isotope dilution liquid chromatography/mass spectrometry analysis of glutathione and glutathione disulfide. Rapid Communications in Mass Spectrometry, 22, 432–440.
Watson, W. P., & Mutti, A. (2004). Role of biomarkers in monitoring exposures to chemicals: present position, future prospects. Biomarkers, 9, 211–242.
Porter, N. A., Caldwell, S. E., & Mills, K. A. (1995). Mechanisms of free radical oxidation of unsaturated lipids. Lipids, 30, 277–290.
Marnett, L. J. (2000). Oxyradicals and DNA damage. Carcinogenesis, 21, 361–370.
Marnett, L. J., Riggins, J. N., & West, J. D. (2003). Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. Journal of Clinical Investigation, 111, 583–593.
Marnett, L. J. (2002). Oxy radicals, lipid peroxidation and DNA damage. Toxicology, 181–182, 219–222.
Horton, A. A., & Fairhurst, S. (1987). Lipid peroxidation and mechanisms of toxicity. Critical Reviews in Toxicology, 18, 27–79.
Völkel, W., Sicilia, T., Pahler, A., Gsell, W., Tatschner, T., Jellinger, K., et al. (2006). Increased brain levels of 4-hydroxy-2-nonenal glutathione conjugates in severe Alzheimer's disease. Neurochemistry International, 48, 679–686.
Jenner, P. (2003). Oxidative stress in Parkinson's disease. Annals of Neurology, 53(Suppl 3), S26–S36.
Butterfield, D. A., & Lauderback, C. M. (2002). Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radical Biology & Medicine, 32, 1050–1060.
Heinecke, J. W. (2002). Oxidized amino acids: culprits in human atherosclerosis and indicators of oxidative stress. Free Radical Biology & Medicine, 32, 1090–1101.
Brash, A. R. (1999). Lipoxygenases: occurrence, functions, catalysis, and acquisition of substrate. Journal of Biological Chemistry, 274, 23679–23682.
Laneuville, O., Breuer, D. K., Xu, N., Huang, Z. H., Gage, D. A., & Watson, J. T. (1995). Fatty acid substrate specificities of human prostaglandin-endoperoxide H synthase-1 and -2. Formation of 12-hydroxy-(9Z, 13E/Z, 15Z)- octadecatrienoic acids from alpha-linolenic acid. Journal of Biological Chemistry, 270, 19330–19336.
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010). Cancer statistics, 2010. CA: A Cancer Journal for Clinicians, 60, 277–300.
Jemal, A., Thomas, A., Murray, T., & Thun, M. (2002). Cancer statistics, 2002. CA: A Cancer Journal for Clinicians, 52, 23–47.
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011). Global cancer statistics. CA: A Cancer Journal for Clinicians, 61, 69–90.
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2001). Estimating the world cancer burden: Globocan 2000. International Journal of Cancer, 94, 153–156.
Futreal, P. A., Coin, L., Marshall, M., Down, T., Hubbard, T., Wooster, R., et al. (2004). A census of human cancer genes. Nature Reviews Cancer, 4, 177–183.
Vogelstein, B., & Kinzler, K. W. (2004). Cancer genes and the pathways they control. Nature Medicine, 10, 789–799.
Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467, 1114–1117.
Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., van de Putte, L. B., et al. (1998). Cyclooxygenase in biology and disease. The FASEB Journal, 12, 1063–1073.
Pong, S. S., Hong, S. L., & Levine, L. (1977). Prostaglandin production by methylcholanthrene-transformed mouse BALB/3T3. Requirement for protein synthesis. Journal of Biological Chemistry, 252, 1408–1413.
Hassid, A., & Levine, L. (1977). Induction of fatty acid cyclooxygenase activity in canine kidney cells (MDCK) by benzo(a)pyrene. Journal of Biological Chemistry, 252, 6591–6593.
Hla, T., & Neilson, K. (1992). Human cyclooxygenase-2 cDNA. Proceedings of the National Academy of Sciences USA, 89, 7384–7388.
Tazawa, R., Xu, X. M., Wu, K. K., & Wang, L. H. (1994). Characterization of the genomic structure, chromosomal location and promoter of human prostaglandin H synthase-2 gene. Biochemical and Biophysical Research Communications, 203, 190–199.
Rizzo, M. T. (2011). Cyclooxygenase-2 in oncogenesis. Clinica Chimica Acta, 412, 671–687.
Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., & Dubois, R. N. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 107, 1183–1188.
Zimmermann, K. C., Sarbia, M., Weber, A. A., Borchard, F., Gabbert, H. E., & Schror, K. (1999). Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Research, 59, 198–204.
Goulet, A. C., Einsphar, J. G., Alberts, D. S., Beas, A., Burk, C., Bhattacharyya, A., et al. (2003). Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biology & Therapy, 2, 713–718.
Tucker, O. N., Dannenberg, A. J., Yang, E. K., Zhang, F., Teng, L., Daly, J. M., et al. (1999). Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Research, 59, 987–990.
Richardsen, E., Uglehus, R. D., Due, J., Busch, C., & Busund, L. T. (2010). COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiology, 34, 316–322.
Mrena, J., Wiksten, J. P., Kokkola, A., Nordling, S., Ristimaki, A., & Haglund, C. (2010). COX-2 is associated with proliferation and apoptosis markers and serves as an independent prognostic factor in gastric cancer. Tumor Biology, 31, 1–7.
Denkert, C., Winzer, K. J., & Hauptmann, S. (2004). Prognostic impact of cyclooxygenase-2 in breast cancer. Clinical Breast Cancer, 4, 428–433.
Denkert, C., Winzer, K. J., Muller, B. M., Weichert, W., Pest, S., Kobel, M., et al. (2003). Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer, 97, 2978–2987.
Yan, M., Rerko, R. M., Platzer, P., Dawson, D., Willis, J., Tong, M., et al. (2004). 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. Proceedings of the National Academy of Sciences USA, 101, 17468–17473.
Chou, W. L., Chuang, L. M., Chou, C. C., Wang, A. H., Lawson, J. A., FitzGerald, G. A., et al. (2007). Identification of a novel prostaglandin reductase reveals the involvement of prostaglandin E2 catabolism in regulation of peroxisome proliferator-activated receptor gamma activation. Journal of Biological Chemistry, 282, 18162–18172.
Schuster, V. L. (1998). Molecular mechanisms of prostaglandin transport. Annual Review of Physiology, 60, 221–242.
Nomura, T., Lu, R., Pucci, M. L., & Schuster, V. L. (2004). The two-step model of prostaglandin signal termination: in vitro reconstitution with the prostaglandin transporter and prostaglandin 15 dehydrogenase. Molecular Pharmacology, 65, 973–978.
Backlund, M. G., Mann, J. R., Holla, V. R., Shi, Q., Daikoku, T., Dey, S. K., et al. (2008). Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Research, 68, 9331–9337.
Markowitz, S. D., & Bertagnolli, M. M. (2009). Molecular origins of cancer: molecular basis of colorectal cancer. The New England Journal of Medicine, 361, 2449–2460.
Holla, V. R., Backlund, M. G., Yang, P., Newman, R. A., & Dubois, R. N. (2008). Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prevention Research, 1, 93–99.
Chan, A. T., Giovannucci, E. L., Meyerhardt, J. A., Schernhammer, E. S., Curhan, G. C., & Fuchs, C. S. (2005). Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. Journal of the American Medical Association, 294, 914–923.
Grosser, T., Fries, S., & FitzGerald, G. A. (2006). Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. Journal of Clinical Investigation, 116, 4–15.
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. New England Journal of Medicine, 343(1520–8), 2.
Langman, M. J., Jensen, D. M., Watson, D. J., Harper, S. E., Zhao, P. L., Quan, H., et al. (1999). Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. Journal of the American Medical Association, 282, 1929–1933.
Baron, J. A., Sandler, R. S., Bresalier, R. S., Quan, H., Riddell, R., Lanas, A., et al. (2006). A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology, 131, 1674–1682.
Solomon, S. D., Pfeffer, M. A., McMurray, J. J., Fowler, R., Finn, P., Levin, B., et al. (2006). Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas. Circulation, 114, 1028–1035.
Blair, I. A. (2008). DNA adducts with lipid peroxidation products. Journal of Biological Chemistry, 283, 15545–15549.
Lee, S. H., Rangiah, K., Williams, M. V., Wehr, A. Y., Dubois, R. N., & Blair, I. A. (2007). Cyclooxygenase-2-mediated metabolism of arachidonic acid to 15-oxo-eicosatetraenoic acid by rat intestinal epithelial cells. Chemical Research in Toxicology, 20, 665–1675.
Lee, S. H., Oe, T., & Blair, I. A. (2001). Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science, 292, 2083–2086.
Williams, M. V., Lee, S. H., & Blair, I. A. (2005). Liquid chromatography/mass spectrometry analysis of bifunctional electrophiles and DNA adducts from vitamin C mediated decomposition of 15-hydroperoxyeicosatetraenoic acid. Rapid Communications in Mass Spectrometry, 19, 849–858.
Jian, W., Lee, S. H., Mesaros, C., Oe, T., Silva Elipe, M. V., & Blair, I. A. (2007). A novel 4-oxo-2(E)-nonenal-derived endogenous thiadiazabicyclo glutathione adduct formed during cellular oxidative stress. Chemical Research in Toxicology, 20, 1008–1018.
Zhu, P., Jian, W., & Blair, I. A. (2009). A 4-oxo-2(E)-nonenal-derived glutathione adduct from 15-lipoxygenase-1-mediated oxidation of cytosolic and esterified arachidonic acid. Free Radical Biology & Medicine, 47, 953–961.
Jian, W., Lee, S. H., Williams, M. V., & Blair, I. A. (2009). 5-Lipoxygenase-mediated endogenous DNA damage. Journal of Biological Chemistry, 284, 16799–16807.
Jian, W. Y., Lee, S. H., & Blair, I. A. (2004). Lipoxygenase-mediated endogenous DNA damage. Chemical Research in Toxicology, 17, 1759.
Blair, I. A. (2001). Lipid hydroperoxide-mediated DNA damage. Experimental Gerontology, 36, 1473–1481.
Kühn, H., Walther, M., & Kuban, R. J. (2002). Mammalian arachidonate 15-lipoxygenases structure, function, and biological implications. Prostaglandins & Other Lipid Mediators, 68–69, 263–290.
Chaitidis, P., Schewe, T., Sutherland, M., Kühn, H., & Nigam, S. (1998). 15-Lipoxygenation of phospholipids may precede the sn-2 cleavage by phospholipases A2: reaction specificities of secretory and cytosolic phospholipases A2 towards native and 15-lipoxygenated arachidonoyl phospholipids. Federation of European Biochemical Societies Letters, 434, 437–441.
Lotzer, K., Funk, C. D., & Habenicht, A. J. (2005). The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis. Biochimica et Biophysica Acta, 1736, 30–37.
Lee, S. H., Williams, M. V., Dubois, R. N., & Blair, I. A. (2003). Targeted lipidomics using electron capture atmospheric pressure chemical ionization mass spectrometry. Rapid Communications in Mass Spectrometry, 17, 2168–2176.
Woods, J. W., Evans, J. F., Ethier, D., Scott, S., Vickers, P. J., Hearn, L., et al. (1993). 5-Lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes. The Journal of Experimental Medicine, 178, 1935–1946.
Peters-Golden, M., & Henderson, W. R., Jr. (2005). The role of leukotrienes in allergic rhinitis. Annals of Allergy, Asthma & Immunology, 94, 609–618.
Murphy, R. C., & Gijon, M. A. (2007). Biosynthesis and metabolism of leukotrienes. Biochemical Journal, 405, 379–395.
Werz, O. (2002). 5-Lipoxygenase: cellular biology and molecular pharmacology. Current Drug Targets—Inflammation and Allergy, 1, 23–44.
Sharma, J. N., & Mohammed, L. A. (2006). The role of leukotrienes in the pathophysiology of inflammatory disorders: is there a case for revisiting leukotrienes as therapeutic targets? Inflammopharmacology, 14, 10–16.
Hicks, A., Monkarsh, S. P., Hoffman, A. F., & Goodnow, R., Jr. (2007). Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments. Expert Opinion on Investigational Drugs, 16, 1909–1920.
Wymann, M. P., & Schneiter, R. (2008). Lipid signalling in disease. Nature Reviews Molecular Cell Biology, 9, 162–176.
Peters-Golden, M. (2008). Expanding roles for leukotrienes in airway inflammation. Current Allergy and Asthma Reports, 8, 367–373.
Zhao, L., & Funk, C. D. (2004). Lipoxygenase pathways in atherogenesis. Trends in Cardiovascular Medicine, 14, 191–195.
Fairweather, D., & Frisancho-Kiss, S. (2008). Mast cells and inflammatory heart disease: potential drug targets. Cardiovascular & Hematological Disorders Drug Targets, 8, 80–90.
Gupta, S., Srivastava, M., Ahmad, N., Sakamoto, K., Bostwick, D. G., & Mukhtar, H. (2001). Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. Cancer, 91, 737–743.
Hennig, R., Ding, X. Z., Tong, W. G., Schneider, M. B., Standop, J., Friess, H., et al. (2002). 5-Lipoxygenase and leukotriene B(4) receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. American Journal of Pathology, 161, 421–428.
Chen, X., Sood, S., Yang, C. S., Li, N., & Sun, Z. (2006). Five-lipoxygenase pathway of arachidonic acid metabolism in carcinogenesis and cancer chemoprevention. Current Cancer Drug Targets, 6, 613–622.
Schulam, P. G., & Shearer, W. T. (1990). Evidence for 5-lipoxygenase activity in human B cell lines. A possible role for arachidonic acid metabolites during B cell signal transduction. Journal of Immunology, 144, 2696–2701.
el Makhour-Hojeij, Y., Baclet, M. C., Chable-Rabinovitch, H., Beneytout, J. L., & Cook, J. (1994). Expression of 5-lipoxygenase in lymphoblastoid B and T cells. Prostaglandins, 48, 21–29.
Lee, S. H., Williams, M. V., & Blair, I. A. (2005). Targeted chiral lipidomics analysis. Prostaglandins & Other Lipid Mediators, 77, 141–157.
Lee, S. H., & Blair, I. A. (2007). Targeted chiral lipidomics analysis by liquid chromatography electron capture atmospheric pressure chemical ionization mass spectrometry (LC-ECAPCI/MS). Methods in Enzymology, 433, 159–174.
Jian, W., Lee, S. H., Arora, J. S., Silva Elipe, M. V., & Blair, I. A. (2005). Unexpected formation of etheno-2′-deoxyguanosine adducts from 5(S)-hydroperoxyeicosatetraenoic acid: evidence for a bis-hydroperoxide intermediate. Chemical Research in Toxicology, 18, 599–610.
Lee, S. H., & Blair, I. A. (2000). Characterization of 4-oxo-2-nonenal as a novel product of lipid peroxidation. Chemical Research in Toxicology, 13, 698–702.
Lee, S. H., Oe, T., & Blair, I. A. (2002). 4,5-Epoxy-2(E)-decenal-induced formation of 1, N(6)-etheno-2′-deoxyadenosine and 1, N(2)-etheno-2′-deoxyguanosine adducts. Chemical Research in Toxicology, 15, 300–304.
Lee, S. H., Elipe, M. V. S., Arora, J. S., & Blair, I. A. (2005). Dioxododecenoic acid: a lipid hydroperoxide-derived bifunctional electrophile responsible for etheno DNA adduct formation. Chemical Research in Toxicology, 18, 566–578.
Lee, S. H., Arora, J. A., Oe, T., & Blair, I. A. (2005). 4-Hydroperoxy-2-nonenal-induced formation of 1, N 2-etheno-2′-deoxyguanosine adducts. Chemical Research in Toxicology, 18, 780–786.
Swenberg, J. A., Bogdanffy, M. S., Ham, A., Holt, S., Kim, A., Morinello, E. J., et al. (1999). Formation and repair of DNA adducts in vinyl chloride- and vinyl fluoride-induced carcinogenesis. International Agency for Research on Cancer Scientific Publication, 150, 29–43.
Barbin, A., & Bartsch, H. (1986). Mutagenic and promutagenic properties of DNA adducts formed by vinyl chloride metabolites. International Agency for Research on Cancer Scientific Publication, 70, 345–358.
Akasaka, S., & Guengerich, F. P. (1999). Mutagenicity of site-specifically located 1, N 2-ethenoguanine in Chinese hamster ovary cell chromosomal DNA. Chemical Research in Toxicology, 12, 501–507.
Winter, C. K., Segall, H. J., & Haddon, W. F. (1986). Formation of cyclic adducts of deoxyguanosine with the aldehydes trans-4-hydroxy-2-hexenal and trans-4-hydroxy-2-nonenal in vitro. Cancer Research, 46, 5682–5686.
Poli, G., Biasi, F., & Leonarduzzi, G. (2008). 4-Hydroxynonenal–protein adducts: a reliable biomarker of lipid oxidation in liver diseases. Molecular Aspects of Medicine, 29, 67–71.
Hankin, J. A., Jones, D. N., & Murphy, R. C. (2003). Covalent binding of leukotriene A4 to DNA and RNA. Chemical Research in Toxicology, 16, 551–561.
Rindgen, D., Nakajima, M., Wehrli, S., Xu, K., & Blair, I. A. (1999). Covalent modifications to 2′-deoxyguanosine by 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chemical Research in Toxicology, 12, 1195–1204.
Lee, S. H., Rindgen, D., Bible, R. H., Jr., Hajdu, E., & Blair, I. A. (2000). Characterization of 2′-deoxyadenosine adducts derived from 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chemical Research in Toxicology, 13, 565–574.
Rindgen, D., Lee, S. H., Nakajima, M., & Blair, I. A. (2000). Formation of a substituted 1, N(6)-etheno-2′-deoxyadenosine adduct by lipid hydroperoxide-mediated generation of 4-oxo-2-nonenal. Chemical Research in Toxicology, 13, 846–852.
Pollack, M., Oe, T., Lee, S. H., Silva Elipe, M. V., Arison, B. H., & Blair, I. A. (2003). Characterization of 2′-deoxycytidine adducts derived from 4-oxo-2-nonenal, a novel lipid peroxidation product. Chemical Research in Toxicology, 16, 893–900.
Pollack, M., Yang, I. Y., Kim, H. Y., Blair, I. A., & Moriya, M. (2006). Translesion DNA synthesis across the heptanone–etheno-2′-deoxycytidine adduct in cells. Chemical Research in Toxicology, 19, 1074–1079.
Yang, I. Y., Hashimoto, K., de Wind, N., Blair, I. A., & Moriya, M. (2009). Two distinct translesion synthesis pathways across a lipid peroxidation-derived DNA adduct in mammalian cells. Journal of Biological Chemistry, 284, 191–198.
Ohmori, H., Friedberg, E. C., Fuchs, R. P., Goodman, M. F., Hanaoka, F., Hinkle, D., et al. (2001). The Y-family of DNA polymerases. Molecular Cell, 8, 7–8.
Dubois, R. N., & Smalley, W. E. (1996). Cyclooxygenase, NSAIDs, and colorectal cancer. Journal of Gastroenterology, 31, 898–906.
Lee, S. H., Williams, M. V., Dubois, R. N., & Blair, I. A. (2005). Cyclooxygenase-2-mediated DNA damage. Journal of Biological Chemistry, 280, 28337–28346.
Brown, J. R., & Dubois, R. N. (2005). COX-2: a molecular target for colorectal cancer prevention. Journal of Clinical Oncology, 23, 2840–2855.
Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., et al. (1996). Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology, 111, 1134–1140.
Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., et al. (1996). Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87, 803–809.
Williams, M. V., Lee, S. H., Pollack, M., & Blair, I. A. (2006). Endogenous lipid hydroperoxide-mediated DNA-adduct formation in min mice. Journal of Biological Chemistry, 281, 10127–10133.
Chou, P. H., Kageyama, S., Matsuda, S., Kanemoto, K., Sasada, Y., Oka, M., et al. (2010). Detection of lipid peroxidation-induced DNA adducts caused by 4-oxo-2(E)-nonenal and 4-oxo-2(E)-hexenal in human autopsy tissues. Chemical Research in Toxicology, 23, 1442–1448.
Blackford, A., Serrano, O. K., Wolfgang, C. L., Parmigiani, G., Jones, S., Zhang, X., et al. (2009). SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clinical Cancer Research, 15, 4674–4679.
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008). Cancer-related inflammation. Nature, 454, 436–444.
Waddell, W. R., Ganser, G. F., Cerise, E. J., & Loughry, R. W. (1989). Sulindac for polyposis of the colon. The American Journal of Surgery, 157, 175–179.
Acknowledgments
This work was supported by NIH grants R01CA091016, P30ES013508, and R25CA101871.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Speed, N., Blair, I.A. Cyclooxygenase- and lipoxygenase-mediated DNA damage. Cancer Metastasis Rev 30, 437–447 (2011). https://doi.org/10.1007/s10555-011-9298-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-011-9298-8